학술논문
Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries
Document Type
article
Author
Joan Brunet; Josep Tabernero; Salvatore Grisanti; Matteo Lambertini; George Pentheroudakis; Bruno Vincenzi; Dirk Arnold; Juan Aguilar-Company; Paolo Pedrazzoli; Solange Peters; Luis Castelo-Branco; Emanuela Romano; Olivier Michielin; Ramon Salazar; Alessio Cortellini; Rossana Berardi; Aleix Prat; Spyridon Gennatas; Giuseppe Tonini; Urania Dafni; Kevin J Harrington; Paola Queirolo; David J Pinato; Francesca Mazzoni; David Viñal; Gino M Dettorre; Uma Mukherjee; Mark Bower; Alexia Bertuzzi; Ailsa Sita-Lumsden; Federica Biello; Andrea Patriarca; Alessandra Gennari; Maura Rossi; Zoi Tsourti; Vasileios Angelis; Jacobo Rogado; Teresa Alonso-Gordoa; Georgia Dimopoulou; Sylvain Pradervand; Marco Tucci; Fanny Pommeret; Marco Krengli
Source
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 11 (2022)
Subject
Language
English
ISSN
2022-0057
2051-1426
2051-1426
Abstract
Background As management and prevention strategies against COVID-19 evolve, it is still uncertain whether prior exposure to immune checkpoint inhibitors (ICIs) affects COVID-19 severity in patients with cancer.Methods In a joint analysis of ICI recipients from OnCovid (NCT04393974) and European Society for Medical Oncology (ESMO) CoCARE registries, we assessed severity and mortality from SARS-CoV-2 in vaccinated and unvaccinated patients with cancer and explored whether prior immune-related adverse events (irAEs) influenced outcome from COVID-19.Findings The study population consisted of 240 patients diagnosed with COVID-19 between January 2020 and February 2022 exposed to ICI within 3 months prior to COVID-19 diagnosis, with a 30-day case fatality rate (CFR30) of 23.6% (95% CI 17.8 to 30.7%). Overall, 42 (17.5%) were fully vaccinated prior to COVID-19 and experienced decreased CFR30 (4.8% vs 28.1%, p=0.0009), hospitalization rate (27.5% vs 63.2%, p